RecruitingNot ApplicableNCT06892171

The Study of the Phenotype of Hereditary Xerocytosis


Sponsor

Centre Hospitalier Universitaire, Amiens

Enrollment

20 participants

Start Date

Mar 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Hereditary xerocytosis is a dominant red blood cell membrane disorder characterized by an increased leakage of potassium from the interior to the exterior of the red blood cell membrane, leading to water loss, red cell dehydration, and chronic hemolysis. In 90% of cases, it is associated with heterozygous gain-of-function mutations in PIEZO1, a gene that encodes a mechanotransducer responsible for converting mechanical stimuli into biological signals. The remaining 10% of cases are linked to mutations in the GARDOS channel gene.


Eligibility

Min Age: 10 Years

Inclusion Criteria3

  • Any patient diagnosed with hereditary xerocytosis according to the 2021 PNDS guidelines
  • Covered by a social security plan
  • Signature of the consent form for study participation by the patient, or for minors, by the parent(s)/legal representative(s).

Exclusion Criteria1

  • patients with other hemolysis reason

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALBlood sample

blood sample for genetic analysis


Locations(1)

CHRU Amiens

Amiens, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06892171


Related Trials